PCOS Is Now PMOS: Why the Name Changed and How to Get Diagnosed

A patient sat down last week and said the line I hear over and over: I have been irregular since I was 14. I have been on birth control most of my adult life. Now I am off it because we want a baby, and nothing happens. Three different doctors told me it was probably stress. When I ran the right labs, the diagnosis was obvious within a week. She is 32. She had been carrying this without a name for 18 years. This article walks through the new name (PMOS), the diagnostic criteria, why it gets missed so often, what to ask for, and what a real workup looks like.

What Is PMOS and Why Did the Name Change?

Polyendocrine metabolic ovarian syndrome (PMOS) is the new official name for the condition previously called polycystic ovary syndrome (PCOS). The renaming was published in The Lancet on May 12, 2026, after a 14-year global consensus process that included more than 14,000 participants from 56 academic, clinical, and patient organizations. The previous name had three specific problems:

1. "Polycystic" is medically inaccurate. What ultrasound shows in this condition is not pathological cysts. The ovaries contain a higher-than-typical number of small follicles (immature egg-containing sacs), which is a normal cell type behaving normally in a hormonally abnormal environment. There is no actual rise in ovarian cysts.
2. "Ovary syndrome" obscures the rest of the picture. The condition is fundamentally an endocrine and metabolic disorder. Insulin resistance, elevated androgens, altered LH/FSH ratio, dyslipidemia, increased visceral adiposity, sleep disruption, mood symptoms, and inflammation are core features. The ovary is one organ in a multisystem story.
3. The name has contributed to under-diagnosis. When patients and clinicians both assume the issue is ovarian, the workup focuses on ultrasound and gynecology, and the metabolic and endocrine work that actually matters gets skipped or delayed for years.

The new name keeps "ovarian" because the reproductive effects are real, but it leads with the truth: polyendocrine (multiple hormone axes) and metabolic. A 3-year transition is planned. The 2028 update of the International Guideline (the document used by clinicians in 195 countries) will integrate PMOS as the primary term.

How Common Is PMOS?

PMOS affects about 1 in 8 women globally, roughly 10 to 13% of reproductive-age women. That is more than 170 million women worldwide. By comparison, type 1 diabetes affects roughly 0.5%. PMOS is many times more common, yet typical clinical attention to it is a small fraction of what is given to diabetes. The prevalence is higher in certain ancestral backgrounds. South Asian, Middle Eastern, and some Hispanic populations show higher rates and often more severe metabolic features at lower body weights. Family history of PMOS, type 2 diabetes, or early cardiovascular disease all raise risk.

What Are the 2023 Diagnostic Criteria?

The 2023 International Evidence-based Guideline, led by Helena Teede and colleagues and published in the Journal of Clinical Endocrinology and Metabolism, defines PMOS by 2 of 3 features in adult women:

1. Clinical or biochemical hyperandrogenism. Clinical signs include hirsutism (unwanted dark hair on the face, chest, or abdomen), persistent acne (often jawline and chin), or androgenic scalp hair thinning. Biochemical signs include elevated total or free testosterone, elevated DHEAS, or an elevated free androgen index.
2. Ovulatory dysfunction. Irregular cycles (typically over 35 days apart or fewer than 8 cycles per year in adults), or anovulation confirmed by mid-luteal progesterone testing.
3. Polycystic ovarian morphology on ultrasound, OR (new in 2023) an elevated serum anti-Müllerian hormone (AMH).

A few specifics that matter in clinic:

• AMH is the biggest practical change for diagnosis. The 2023 guideline added serum AMH as an alternative to transvaginal ultrasound for the "polycystic morphology" criterion. AMH is a simple blood test. It removed the biggest practical barrier (booking, paying for, and tolerating a pelvic ultrasound) that delayed many diagnoses for years.
• If hyperandrogenism and irregular cycles are both present, no imaging or AMH is required. The diagnosis is complete with those two features.
• In adolescents, the bar is stricter. Both hyperandrogenism and ovulatory dysfunction must be present. Ultrasound and AMH are not used in adolescents because both can be misleading during normal puberty.
• Other conditions that look like PMOS must be ruled out first. This is the step most often skipped. Thyroid dysfunction, hyperprolactinemia, non-classical congenital adrenal hyperplasia, Cushing syndrome, and ovarian or adrenal tumors can mimic PMOS features. A proper workup screens for each.

What Labs Should I Ask For?

A complete first-pass PMOS workup, in my practice, looks like this. Numbers in parentheses are the rough targets we discuss in the visit. Reproductive hormones (day 2 to 5 of cycle if cycling, any day if amenorrheic):

• Total testosterone and free testosterone (often elevated)
• SHBG (often low, which amplifies free testosterone biological effect)
• DHEAS (adrenal androgen)
• 17-OH progesterone (rules out non-classical congenital adrenal hyperplasia, often missed)
• LH and FSH (the classic LH:FSH ratio over 2:1 supports PMOS but is not required)
• Estradiol
• AMH (replaces ultrasound for many patients per 2023 guideline)
• Progesterone if testing for anovulation on a long cycle

Metabolic and endocrine context:

• Fasting insulin (target < 6 µIU/mL; insulin resistance starts above 6)
• Fasting glucose and hemoglobin A1C
• Lipid panel with ApoB (PMOS often shows elevated triglycerides and low HDL)
• TSH, free T4, free T3 (rules out thyroid; thyroid dysfunction often coexists)
• Prolactin (rules out a prolactinoma, which can mimic the cycle picture)
• 25-hydroxy vitamin D (deficiency is common and worsens insulin resistance)
• hs-CRP (low-grade inflammation marker)

Imaging only when needed:

• Pelvic ultrasound if AMH is borderline or if a structural concern (fibroids, cysts of a different kind, masses) is on the differential.

This is the panel I run on day one. It usually answers the question by the end of the week.

Guidance from the Clinic

Why Does PMOS Get Missed for So Long?

PMOS gets missed for a structural reason and a clinical reason that compound each other. Structural reason: short visits and incomplete labs. A 15-minute insurance-based primary care visit is not enough time to take a real menstrual history, weigh the skin and hair findings, build a working differential, and order 12-plus labs across reproductive and metabolic axes. When the testing gets reduced to "TSH, CBC, CMP, lipids," PMOS hides easily. Clinical reason: birth control masks the picture. Many young women are put on combined hormonal contraception in their late teens for irregular cycles or acne. Combined hormonal contraception suppresses LH, FSH, and androgens. The underlying PMOS does not go away; it just stops producing visible symptoms. The diagnosis often does not surface until the patient goes off birth control to try to conceive, and the irregular cycles and infertility come roaring back. A third compounding factor: the old name. When everyone, including the patient, expects an ovarian problem, the workup gets directed at the ovary, and the metabolic core is missed. The new PMOS name should change the default mental model. That is, in part, why the renaming process happened.

What Are the Long-Term Risks if PMOS Is Not Treated?

The long-term risks of untreated PMOS run across three systems, and they are the reason the name change matters clinically and not just semantically.

Metabolic and cardiovascular:

• Two-fold to four-fold increase in type 2 diabetes risk over the lifespan.
• Higher rates of metabolic syndrome, NAFLD (non-alcoholic fatty liver), and dyslipidemia.
• Elevated long-term cardiovascular risk. This is where ApoB, Lp(a), and arterial imaging come in for older patients with a PMOS history.

Reproductive:

• Subfertility and longer time to conception when pregnancy is desired.
• Higher risk of gestational diabetes and preeclampsia during pregnancy.
• Possibly increased risk of endometrial hyperplasia and endometrial cancer in patients with prolonged unopposed estrogen exposure (long anovulatory cycles).

Endocrine, dermatologic, and psychological:

• Persistent hyperandrogenism contributes to acne, hirsutism, and androgenic alopecia.
• Higher rates of depression, anxiety, and disordered eating.
• Sleep apnea is more common, even at lower body weights.

The good news: most of these risks are modifiable when the condition is named and treated.

How Is PMOS Treated?

PMOS treatment is built around the patient's current goals (cycle regulation, fertility, skin/hair, metabolic optimization, or general health) and the metabolic core. Foundation for every patient with PMOS:

• Insulin sensitivity work: protein-forward, lower-glycemic eating; post-meal walking; strength training 2 to 4 times a week; zone 2 cardio 2 to 3 hours a week.
• Inositol: myo-inositol 2,000 mg with D-chiro-inositol 50 mg (the studied 40:1 ratio), twice daily. The Lancet eClinicalMedicine perspectives paper and prior meta-analyses support its role in insulin sensitivity and ovulation, with very low risk.
• Vitamin D and omega-3 correction if deficient.
• Adequate sleep, especially fixing any undiagnosed sleep apnea.

When insulin resistance is significant:

• Metformin, 500 mg titrated up to 1,500 to 2,000 mg daily. Improves ovulation and metabolic markers.
• GLP-1 receptor agonists (semaglutide, tirzepatide) in select patients with significant metabolic dysfunction, when access and cost allow.

For cycle regulation when fertility is not the immediate goal:

• Combined hormonal contraception (the pill, patch, or ring), or a cyclic progestin, to regulate cycles and protect the endometrium.

For androgenic skin and hair symptoms:

• Spironolactone (often 100 to 200 mg daily). Effective; requires reliable contraception in patients who could become pregnant.
• Topical retinoids, minoxidil for hair, and laser hair removal where appropriate.

For fertility:

• Letrozole first-line for ovulation induction (better than clomiphene per the 2023 guideline).
• Referral to reproductive endocrinology when needed.

The plan is personal. Two women with the same diagnosis can have very different treatment because their goals are different.

How Fishtown Medicine Approaches PMOS

At Fishtown Medicine, PMOS is one of the conditions where the practice's structure actually changes the medicine. The visit is 60 to 90 minutes. The lab order on day one is the full panel above, not three or four piecemeal labs across multiple visits. The follow-up is by text, so titrating metformin or inositol is a 2-minute conversation, not a 6-week wait. The workflow:

1. First visit (60 to 90 minutes): full reproductive, metabolic, and dermatologic history. Skin exam. Working diagnosis. Lab order placed before the patient leaves.
2. Labs done locally through Quest or LabCorp, billed to insurance where possible (the membership covers the visit, not the labs themselves).
3. Lab review visit within 1 to 2 weeks: results walked through line by line. Confirmed diagnosis. Phenotype identified.
4. Personalized starter protocol built around the patient's goals.
5. Text-based titration over the first 3 months for inositol, metformin, or other meds.
6. Re-check labs at 3 to 6 months, then every 6 to 12 months once stable.

This is the same continuous-care model the practice uses for everything else. The reason it works for PMOS specifically is that PMOS is a diagnosis-plus-management condition, not a one-shot prescription. Continuous access is what turns a name on a chart into actual results.

The Bottom Line

The renaming of PCOS to PMOS, published in The Lancet on May 12, 2026, is more than a label change. It moves the clinical center of gravity from the ovary to the endocrine and metabolic core, which is where the long-term risk actually lives and where treatment actually works. The condition affects about 1 in 8 women. Most are still going undiagnosed for years. A complete workup is one visit and 12 to 14 labs. If your prior testing did not include AMH, free testosterone, SHBG, DHEAS, and fasting insulin, you have not actually been worked up for PMOS.

Key Takeaways

• PCOS is now PMOS (Polyendocrine Metabolic Ovarian Syndrome), per The Lancet May 12, 2026 consensus.
• About 1 in 8 women have it, and most are still undiagnosed for years.
• 2023 criteria require 2 of 3: hyperandrogenism, ovulatory dysfunction, or polycystic morphology on ultrasound (or elevated AMH).
• AMH is the new low-friction diagnostic option added in 2023, removing the ultrasound barrier for many patients.
• Untreated PMOS carries 2 to 4 times higher type 2 diabetes risk and meaningful cardiovascular, reproductive, and psychological risk.

Scientific References and Sources

1. The Lancet. (2026). "Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process." The Lancet, published May 12, 2026.
2. Teede HJ, Tay CT, Laven J, et al. (2023). "Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome." Journal of Clinical Endocrinology and Metabolism, 108(10), 2447-2469. PMID: 37580314.
3. Endocrine Society. (2026). "Polyendocrine Metabolic Ovarian Syndrome: New name to improve diagnosis and care of condition affecting 170 million women worldwide." Endocrine Society announcement, May 2026.
4. American Society for Reproductive Medicine. "Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome (2023) - Practice Guidance." ASRM Practice Committee.
5. Monash University. "PCOS Guideline Summary 2023." International evidence-based guideline summary.

Medical Disclaimer: This article provides clinical context for educational purposes. In the world of Precision Medicine, there is no "one size fits all"; the right plan must be matched to your unique lab work, physiology, and goals. Consult Dr. Ash or your own clinician to determine if a PCOS / PMOS workup or treatment plan is right for you, especially if you have other chronic conditions, are pregnant or trying to conceive, or are taking other prescription medications.

---

Dr. Ash is a board-certified internal medicine physician at Fishtown Medicine in Philadelphia. The practice runs full-panel hormone and metabolic workups for suspected PCOS / PMOS as part of a single 60- to 90-minute first visit.